Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy

Hematology Journal

Volumn 5, Issue 7, 2005, Pages 559-564

  Buchler, Tomas ^a,d   Krejci, Marta ^a   Svobodnik, Adam ^b   Adam, Zdenek ^a   Minarik, Jiri ^c   Bacovsky, Jaroslav ^c   Scudla, Vlastimil ^c   Mayer, Jiri ^a   Vorlicek, Jiri ^a   Hajek, Roman ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Angiotensin I converting enzyme inhibitors; Hypertension; Multiple myeloma; Peripheral stem cell transplantation; Survival

Indexed keywords

ALBUMIN; ALPHA INTERFERON; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CAPTOPRIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; ENALAPRIL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; LISINOPRIL; MELPHALAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL; VINCRISTINE;

ADULT; AGE DISTRIBUTION; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 20044364749     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200571     Document Type: Article

References (24)

1. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305-1315.
2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
3. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670-1676.
4. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939-945.
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
6. Reddy MK, Baskaran K, Molteni A. Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med 1995; 210: 221-226.
7. Wang R, Zagariya A, Ang E, Ibarra-Sunga O, Uhal BD. Fas-induced apoptosis of alveolar epithelial cells requires ANG II generation and receptor interaction. Am J Physiol 1999; 277: 1245-1250.
8. Boucek Jr RJ, Steele A, Miracle A, Atkinson J. Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol 2003; 3: 319-329.
9. Chisi JE, Briscoe CV, Ezan E, Genet R, Riches AC, Wdzieczak-Bakala J. Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation. Br J Haematol 2000; 109: 563-570.
10. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996; 97: 839-844.
11. Rodgers K, Xiong S, DiZerega GS. Effect of angiotensin II and angiotensin(1-7) on hematopoietic recovery after intravenous chemotherapy. Cancer Chemother Pharmacol 2003; 51: 97-106.
12. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100: 2310-2314.
13. Walther T, Menrad A, Orzechowski HD, Siemeister G, Paul M, Schirner M. Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J 2003; 17: 2061-2067.
14. Koh WP, Yuan JM, Sun CL, van den Berg D, Seow A, Lee HP et al. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res 2003; 63: 573-578.
15. Schweisfurth H, Schmidt M, Brugger E, Maiwald L, Thiel H. Alterations of serum carboxypeptidases N and angiotensin-I-converting enzyme in malignant diseases. Clin Biochem 1985; 18: 242-246.
16. Abali H, Haznedaroglu IC, Goker H, Celik I, Ozatli D, Koray Z et al. Circulating and local bone marrow renin - angiotensin system in leukemic hematopoiesis: preliminary evidences. Hematology 2002; 7: 75-82.
17. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-184.
18. Lindholm LH, Anderson H, Ekbom T, Hansson L, Lanke J, Dahlof B et al. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 2001; 358: 539-544.
19. Romer FK, Emmertsen K. Serum angiotensin-converting enzyme in malignant lymphomas, leukaemia and multiple myeloma. Br J Cancer 1980; 42: 314-318.
20. Hajek R, Scudla V, Krejci M, Bacovsky J, Schutzova M, Koza V et al. Interim analysis of randomized trial 4W of Czech Myeloma Group: maintenance therapy interferon alpha or sequential maintenance therapy interferon alpha and dexamethasone after high-dose chemotherapy and peripheral blood stem cell transplantation in newly diagnosed patients with multiple myeloma [abstract]. Hematol J 2003; 4 (Suppl 1): 230a.
21. Durie B, Salmon S. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842-854.
22. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379-398.
23. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
24. Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99: 3163.